IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET ...

Conclusions: In the OLT setting, the potential benefits of antiviral treatments including PEG-IFN may be limited by the poor tolerability of the adopted drugs. The aim of the present retrospective ...

if previously treated with regimens containing PEG-IFN, ribavirin, and/or sofosbuvir, but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, but pose no safety risk, and may even signal better viral response.

Hepatitis C virus (HCV) is the major cause of liver disease worldwide and a potential source of high morbidity and mortality in the future. The World Health Organization estimates that ...

Interferon gamma (IFN-γ) is a cytokine that induces a series of immune responses against viruses and tumors. The pro-apoptotic, anti-tumor and anti-proliferative actions of the cells are ...

The hepatitis C virus (HCV) is believed to have infected approximately 170 million people worldwide (Fig. 1). Often referred to as the silent killer, patients can remain asymptomatic for decades ...